Detalles de la búsqueda
1.
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Blood;
120(1): 9-19, 2012 Jul 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-22498745
2.
The potential role of pre-transplant HBcIgG seroposivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: a study from the Rome Transplant Network.
Am J Hematol;
87(2): 213-7, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22076952
3.
Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network.
Br J Haematol;
169(2): 293-6, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25371286
4.
Standard- versus high-dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization.
Transfusion;
50(11): 2432-46, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20553434
5.
Effect of high dose cytosine arabinoside on quantitative EEG in patients with acute myeloid leukemia.
Cogn Neurodyn;
10(2): 185-8, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27066155
6.
Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma.
Exp Hematol Oncol;
4: 17, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26120498
Resultados
1 -
6
de 6
1
Próxima >
>>